Pexmetinib (ARRY-614)dual inhibitor of p38 MAPK and Tie2/Tek receptor tyrosine kinase CAS# 945614-12-0 |
- PD 123319 ditrifluoroacetate
Catalog No.:BCC1841
CAS No.:136676-91-0
- Irbesartan
Catalog No.:BCC2560
CAS No.:138402-11-6
- Olmesartan
Catalog No.:BCC1819
CAS No.:144689-24-7
- Tranilast
Catalog No.:BCC2514
CAS No.:53902-12-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 945614-12-0 | SDF | Download SDF |
PubChem ID | 24765037 | Appearance | Powder |
Formula | C31H33FN6O3 | M.Wt | 556.63 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 125 mg/mL (224.57 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea | ||
SMILES | CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NCC3=C(C=CC(=C3)F)OC4=CC5=C(C=C4)N(N=C5)CCO | ||
Standard InChIKey | LNMRSSIMGCDUTP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,39H,13-14,18H2,1-4H3,(H2,33,35,40) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Pexmetinib (ARRY-614) Dilution Calculator
Pexmetinib (ARRY-614) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7965 mL | 8.9826 mL | 17.9653 mL | 35.9305 mL | 44.9131 mL |
5 mM | 0.3593 mL | 1.7965 mL | 3.5931 mL | 7.1861 mL | 8.9826 mL |
10 mM | 0.1797 mL | 0.8983 mL | 1.7965 mL | 3.5931 mL | 4.4913 mL |
50 mM | 0.0359 mL | 0.1797 mL | 0.3593 mL | 0.7186 mL | 0.8983 mL |
100 mM | 0.018 mL | 0.0898 mL | 0.1797 mL | 0.3593 mL | 0.4491 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pexmetinib (ARRY-614) is a potent inhibitor of cytokine synthesis, via the dual inhibition of p38 mitogen-activated protein kinase (MAPK), and Tie2/Tek receptor tyrosine kinase. The in vitro IC50 values of ARR Y-614 for both Tie2 and p38 mitogen-activated protein kinase are 1000 ng/mL and 100 ng/mL, respectively [1, 2].
p38 is a group of mitogen-activated protein kinases. MAPKs are activated by the dual phosphorylation of Tyr and Thr residues in the Thr-Xaa-Tyr motif in subdomain VIII. Data indicated that p38 MAPK may mediate signaling to the nucleus [3].
ARRY-614 is active against MAPK and Tie2/Tek receptor tyrosine kinase in cells. In primary human bone marrow stromal cells, ARRY-614 inhibited basal cytokines with an IC50 value ranging from 50-100 nM [4].
In dose escalation or expansion cohorts, treatment with ARRY-614 either once daily or twice daily was applied to forty-five patients. ARRY-614 reduced the levels of circulating biomarkers and the p38 MAPK activation of bone marrow [1]. In ex vivo stimulated human whole blood, LPS-induced cytokines was inhibited by ARRY-614 with an IC50 value ranging from 50-120 nM. ARRY-614 inhibited the release of IL-6 from SEA- or LPS-challenged mice with an ED50 value less than 10 mg/kg. Combining ARRY-614 with lenalidomide inhibited both pro-inflammatory cytokines and tumor growth in vivo with higher potency, compared with either agent alone [4].
References:
[1]. Garcia-Manero G, Khoury HJ, Jabbour E, et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clinical Cancer Research, 2015, 21(5): 985-994.
[2]. Wollenberg LA, Corson DT, Nugent CA, et al. An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614). Clinical pharmacology: advances and applications, 2015, 7: 87.
[3]. Raingeaud J, Whitmarsh AJ, Barrett T, et al. MKK3-and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Molecular and cellular biology, 1996, 16(3): 1247-1255.
[4]. Winski S, Humphries M, Yeh T, et al. Activity of ARRY-614, an inhibitor of p38 map kinase and angiogenic targets, in hematologic malignancies. Cancer Research, 2009, 69(9 Supplement): 331-331.
- AMG-900
Catalog No.:BCC2175
CAS No.:945595-80-2
- Levcromakalim
Catalog No.:BCC7039
CAS No.:94535-50-9
- 9(11),12-Oleanadien-3-ol
Catalog No.:BCN4499
CAS No.:94530-87-7
- Senkyunolide G
Catalog No.:BCC9143
CAS No.:94530-85-5
- Senkyunolide E
Catalog No.:BCC9142
CAS No.:94530-83-3
- 20-Deoxocarnosol
Catalog No.:BCN3152
CAS No.:94529-97-2
- 3,4-Dihydro-6,7-(methylenedioxy)-2(1H)-quinolinone
Catalog No.:BCN1299
CAS No.:94527-34-1
- 4-Hydroxy-2-methoxyphenol 1-O-(6-O-syringoyl)glucoside
Catalog No.:BCN1300
CAS No.:945259-61-0
- 7-Prenyljacareubin
Catalog No.:BCN7353
CAS No.:94513-60-7
- CYM 5541
Catalog No.:BCC6321
CAS No.:945128-26-7
- Tamibarotene
Catalog No.:BCC1983
CAS No.:94497-51-5
- 2'-Acetylacteoside
Catalog No.:BCN3409
CAS No.:94492-24-7
- (R)-(+)-m-Nitrobiphenyline oxalate
Catalog No.:BCC7525
CAS No.:945618-97-3
- 6-Aldehydo-7-methoxyiso-ophiopogonanone B
Catalog No.:BCC8345
CAS No.:123941-06-0
- 7-O-ethyl-morroniside
Catalog No.:BCN3883
CAS No.:945721-10-8
- XL019
Catalog No.:BCC2057
CAS No.:945755-56-6
- AA 29504
Catalog No.:BCC7829
CAS No.:945828-50-2
- Parisyunnanoside B
Catalog No.:BCN2837
CAS No.:945865-37-2
- Senkyunolide H
Catalog No.:BCN6352
CAS No.:94596-27-7
- Senkyunolide I
Catalog No.:BCN6353
CAS No.:94596-28-8
- LX-1031
Catalog No.:BCC1712
CAS No.:945976-76-1
- RO5126766(CH5126766)
Catalog No.:BCC6374
CAS No.:946128-88-7
- Mulberrofuran K
Catalog No.:BCN7188
CAS No.:94617-36-4
- RN 1734
Catalog No.:BCC7770
CAS No.:946387-07-1
An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614).[Pubmed:26491375]
Clin Pharmacol. 2015 Sep 30;7:87-95.
BACKGROUND: Pexmetinib (ARRY-614) is a dual inhibitor of p38 mitogen-activated protein kinase and Tie2 signaling pathways implicated in the pathogenesis of myelodysplastic syndromes. Previous clinical experience in a Phase I dose-escalation study of myelodysplastic syndrome patients using pexmetinib administered as neat powder-in-capsule (PIC) exhibited high variability in pharmacokinetics and excessive pill burden, prompting an effort to improve the formulation of pexmetinib. METHODS: A relative bioavailability assessment encompassed three parallel treatment cohorts of unique subjects comparing the two new formulations (12 subjects per cohort), a liquid oral suspension (LOS) and liquid-filled capsule (LFC) and the current clinical PIC formulation (six subjects) in a fasted state. The food-effect assessment was conducted as a crossover of the LOS and LFC formulations administered under fed and fasted conditions. Subjects were divided into two groups of equal size to evaluate potential period effects on the food-effect assessment. RESULTS: The geometric mean values of the total plasma exposures based upon area-under-the-curve to the last quantifiable sample (AUClast) of pexmetinib were approximately four- and twofold higher after administration of the LFC and LOS formulations, respectively, than after the PIC formulation, when the formulations were administered in the fasted state. When the LFC formulation was administered in the fed state, pexmetinib AUClast decreased by <5% compared with the fasted state. After administration of the LOS formulation in the fed state, pexmetinib AUClast was 34% greater than observed in the fasted state. CONCLUSION: These results suggest that the LFC formulation of pexmetinib may achieve greater exposures with lower doses due to the greater bioavailability compared to the PIC, and remain unaffected by coadministration with food.